Previous studies, including our own, have demonstrated that IgM and IgA antibodies have been detected against myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), and other neural antigens in subgroups of patients suffering from MS and other neurologic disorders [29–34]. Here, CD79A is linked to myeloid sarcoma.